1.19
-0.05 (-4.03%)
| Penutupan Terdahulu | 1.24 |
| Buka | 1.21 |
| Jumlah Dagangan | 88,624 |
| Purata Dagangan (3B) | 1,884,238 |
| Modal Pasaran | 3,962,530 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.43 |
| Harga / Jualan (P/S) | 0.190 |
| Harga / Buku (P/B) | 203.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Apr 2025 |
| Margin Keuntungan | -102.80% |
| Margin Operasi (TTM) | -69.57% |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 382.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 914.75% |
| Nisbah Semasa (MRQ) | 0.540 |
| Aliran Tunai Operasi (OCF TTM) | -9.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.39 M |
| Pulangan Atas Aset (ROA TTM) | -37.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,708.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Redhill Biopharma Ltd. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.13 |
|
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Institusi | 4.30% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Your Advocates Ltd., Llp | 30 Sep 2025 | 19 |
| Rothschild Investment Llc | 30 Sep 2025 | 17 |
| Financial Management Professionals, Inc. | 30 Sep 2025 | 0 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Dec 2025 | Pengumuman | RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement |
| 04 Nov 2025 | Pengumuman | RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement |
| 22 Oct 2025 | Pengumuman | RedHill Biopharma Receives Nasdaq Staff Determination Notification |
| 20 Oct 2025 | Pengumuman | CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO |
| 20 Oct 2025 | Pengumuman | RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal |
| 06 Oct 2025 | Pengumuman | RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® |
| 29 Sep 2025 | Pengumuman | RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |